Access to Medicines for Parkinson's Disease in Kenya: A Qualitative Exploration.

IF 2.6 4区医学 Q2 CLINICAL NEUROLOGY Movement Disorders Clinical Practice Pub Date : 2024-08-21 DOI:10.1002/mdc3.14192

Natasha Fothergill-Misbah, Juzar Hooker, Judith Kwasa, Richard Walker

{"title":"Access to Medicines for Parkinson's Disease in Kenya: A Qualitative Exploration.","authors":"Natasha Fothergill-Misbah, Juzar Hooker, Judith Kwasa, Richard Walker","doi":"10.1002/mdc3.14192","DOIUrl":null,"url":null,"abstract":"Background: The accessibility of Parkinson's disease medicines is limited across sub-Saharan Africa, which can have negative health, social and financial consequences for people with Parkinson's disease and their families. However, there is a stark gap in the literature regarding the impact of poor access to medicines on individuals.Objectives: The study objective was to understand the accessibility of Parkinson's disease medicines in Kenya from the perspective of people with Parkinson's disease, their caregivers and neurologists.Methods: In-depth qualitative interviews were conducted with 55 people with Parkinson's disease, 23 caregivers and 8 neurologists to understand their experience regarding challenges with accessing Parkinson's disease medicines and the health, social and financial impact of poor availability and affordability.Results: Medicines for Parkinson's disease were deemed to be largely unavailable and unaffordable across Kenya. People with Parkinson's disease, caregivers and neurologists expressed the financial burden caused by long-term treatment in the absence of health insurance coverage. Further, barriers accessing medicines negatively impacted symptom control, social relations, and quality of life.Conclusions: Access to Parkinson's disease medicines in Kenya is limited, with severe implications for symptom management and quality of life. People with Parkinson's disease should be able to access and afford the medicines they need to manage their condition.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.14192","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The accessibility of Parkinson's disease medicines is limited across sub-Saharan Africa, which can have negative health, social and financial consequences for people with Parkinson's disease and their families. However, there is a stark gap in the literature regarding the impact of poor access to medicines on individuals.

Objectives: The study objective was to understand the accessibility of Parkinson's disease medicines in Kenya from the perspective of people with Parkinson's disease, their caregivers and neurologists.

Methods: In-depth qualitative interviews were conducted with 55 people with Parkinson's disease, 23 caregivers and 8 neurologists to understand their experience regarding challenges with accessing Parkinson's disease medicines and the health, social and financial impact of poor availability and affordability.

Results: Medicines for Parkinson's disease were deemed to be largely unavailable and unaffordable across Kenya. People with Parkinson's disease, caregivers and neurologists expressed the financial burden caused by long-term treatment in the absence of health insurance coverage. Further, barriers accessing medicines negatively impacted symptom control, social relations, and quality of life.

Conclusions: Access to Parkinson's disease medicines in Kenya is limited, with severe implications for symptom management and quality of life. People with Parkinson's disease should be able to access and afford the medicines they need to manage their condition.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肯尼亚帕金森病药物的获取：定性探索。

背景：在撒哈拉以南非洲地区，帕金森病药物的可及性非常有限，这可能会对帕金森病患者及其家人的健康、社会和经济造成负面影响。然而，关于药物获取困难对个人的影响，文献中还存在明显的空白：研究旨在从帕金森病患者、其护理人员和神经科医生的角度了解肯尼亚帕金森病药物的可及性：对 55 名帕金森病患者、23 名护理人员和 8 名神经科医生进行了深入的定性访谈，以了解他们在获取帕金森病药物方面遇到的挑战，以及药物供应不足和价格低廉对健康、社会和经济造成的影响：结果：在肯尼亚全国，帕金森病药物基本上都无法买到，也负担不起。帕金森病患者、护理人员和神经科医生表示，在没有医疗保险的情况下，长期治疗会造成经济负担。此外，获得药物的障碍对症状控制、社会关系和生活质量产生了负面影响：结论：在肯尼亚，帕金森病患者获得药物的机会有限，严重影响了症状控制和生活质量。帕金森病患者应该能够获得并负担得起控制病情所需的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Movement Disorders Clinical Practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

7.50%

发文量

218

期刊介绍： Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)

期刊最新文献

Early-Onset Isolated Dystonia Associated with COL6A3 Mutation Responsive to Deep Brain Stimulation. In Memoriam Kapil Sethi, M.D. (1953-2024). A Novel ANO3 Gene Mutation Associated with a Dystonia-Ataxia Syndrome. Validation of a 5-Year Prognostic Model for Parkinson's Disease. Dystonic Tremor as Main Clinical Manifestation of SCA21.